ARTES offers a range of biosimilar producing cell lines and processes for out-licensing and technology transfer. All listed cell lines are based on our safe and high yield expression system Hansenula polymorpha.

Inter­feron alpha2amar­keted in Mena region; new tech­nol­ogy with improved yield; PEGy­lated process available
Inter­feron alpha2blicensed to India; PEGy­lated process available
Hirudinmar­keted in Mena region; new tech­nol­ogy with improved yield avail­able
Hiruloglicensed to Egypt; cell line and process available
Insulincell line and process as mar­keted in India avail­able; new 2nd gen­er­a­tion tech­nol­ogy with improved yield under devel­op­ment; 2nd gen­er­a­tion tech­nol­ogy devel­op­ment time: approx. 12 months
Lisproproof-of-concept for expres­sion achieved; cell line & process to be devel­oped; devel­op­ment time: approx. 12 months
Glargineproof-of-concept for expres­sion achieved; cell line & process to be devel­oped; devel­op­ment time: approx. 12 months
G-CSFcell line avail­able; process to be devel­oped; devel­op­ment time: approx. 9 months
GM-CSFproof-of-concept for expres­sion achieved; cell line & process to be devel­oped; devel­op­ment time: approx. 12 months
hGrowth Hor­moneproof-of-concept for expres­sion achieved; cell line & process to be devel­oped; devel­op­ment time: approx. 12 months
Staphy­lok­i­nasecell line avail­able; process to be devel­oped; devel­op­ment time approx. 9 months

To obtain a quote, please con­tact us at info(at)artes-biotechnology.com indi­cat­ing name of the biosimilar process of interest to you. We will revert to you with a ded­i­cated offer spec­i­fy­ing deliv­ery times and costs.